Abstract
Adoptive cell therapy using endogenous T cells involves the ex vivo isolation and expansion of antigen-specific T cells fromthe peripheral blood and is uniquely suited for validating and translating antigen discovery. Endogenous T-cell therapy does not require accessible tumor as a source of infiltrating T cells and is free of regulatory and logistical constraints associated with engineering T cells. Candidate epitope peptides identified through antigen discovery may be rapidly implemented as targets in clinical trials of endogenous T-cell therapy and even incorporated as an "ad hoc" approach to personalized treatment when autologous tumor is available. Several firstin- human studies using a uniform population of antigen-specific T cells defined by phenotype and specificity have provided a means to confirm candidate antigens as potential tumor rejection antigens and to evaluate the reasons for success or failure using as a "transferrable cellular biomarker" the adoptively transferred T cells.
Original language | English (US) |
---|---|
Pages (from-to) | 144-148 |
Number of pages | 5 |
Journal | Cancer Journal (United States) |
Volume | 23 |
Issue number | 2 |
DOIs | |
State | Published - 2017 |
Keywords
- Adoptive cell therapy
- ETC therapy
- Endogenous T cells
- Transferrable cellular biomarker
ASJC Scopus subject areas
- Oncology
- Cancer Research